产品号 #07980_C
Cell culture supplement
概述
Heparin is a mucopolysaccharide with anticoagulant properties. It supports the binding of fibroblast growth factor (FGF) to its receptor and increases the stability of FGF. Heparin is used together with epidermal growth factor (EGF) and FGF in NeuroCult™ media for the culture of embryonic rat or adult human neural stem and progenitor cells, and adult mouse neural stem and progenitor cells. For complete instructions, refer to the Technical Manual: In Vitro Proliferation and Differentiation of Neural Stem and Progenitor Cells Using NeuroCult™ (Human; Document #28724 or Mouse/Rat; Document #28725), available at www.stemcell.com or contact us to request a copy.
Heparin Solution is also required as a supplement in various other STEMCELL culture media, including MammoCult™ Human Medium Kit (Catalog #05620), EpiCult™-B Mouse Medium Kit (Catalog #05610), and EC-Cult™-XF Culture Kit (Catalog #08000).
Contains
0.2% (2 mg/mL; 360 IU/mL) Heparin sodium salt in phosphate-buffered saline (PBS)
Subtype
Supplements
Cell Type
Mammary Cells, Neural Stem and Progenitor Cells, Other, Prostate Cells
Species
Human, Rat
Application
Cell Culture
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (3)
Publications (1)
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncology 2011 SEP
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer, and despite treatment advances, patient prognosis remains poor. During routine animal studies, we serendipitously observed that fenbendazole, a benzimidazole antihelminthic used to treat pinworm infection, inhibited brain tumor engraftment. Subsequent in vitro and in vivo experiments with benzimidazoles identified mebendazole as the more promising drug for GBM therapy. In GBM cell lines, mebendazole displayed cytotoxicity, with half-maximal inhibitory concentrations ranging from 0.1 to 0.3 µM. Mebendazole disrupted microtubule formation in GBM cells, and in vitro activity was correlated with reduced tubulin polymerization. Subsequently, we showed that mebendazole significantly extended mean survival up to 63% in syngeneic and xenograft orthotopic mouse glioma models. Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans. Our findings indicate that mebendazole is a possible novel anti-brain tumor therapeutic that could be further tested in clinical trials.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
